Meropenem/vaborbactam

Drug Profile

Meropenem/vaborbactam

Alternative Names: Carbavance; Meropenem/RPX-7009; RPX-2014/RPX-7009; RPX-7009/RPX-2014

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Rempex Pharmaceuticals
  • Developer The Medicines Company; US Department of Health and Human Services
  • Class Antibacterials; Pyrrolidines; Small molecules; Thienamycins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Urinary tract infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bacteraemia; Gram-negative infections; Pneumonia; Pyelonephritis; Urinary tract infections

Most Recent Events

  • 15 Dec 2016 The Medicines Company plans the phase III TANGO 3 trial for Pneumonia in the US and the EU (NCT03006679)
  • 26 Oct 2016 Antimicrobial data from a phase III trial in Gram-negative infections (Treatment-resistant) presented at the IDWeek 2016 (IDW - 2016)
  • 01 Jul 2016 Phase-I clinical trials in Gram-negative infections (In infants, In children, In adolescents) in USA (IV) (NCT02687906)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top